<DOC>
	<DOCNO>NCT02732184</DOCNO>
	<brief_summary>This first study safety increase dose level AEB1102 patient Relapsed Refractory Acute Myeloid Leukemia Myelodysplastic Syndrome . The study also evaluate amount AEB1102 blood , effect AEB1102 blood amino acid level antitumor effect AEB1102 .</brief_summary>
	<brief_title>A Multiple Dose , Dose Escalation Trial AEB1102 Patients With AML MDS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Willing able provide inform consent Age 18 old Diagnosis AML MDS accord WHO criteria AML relapse refractory least one attempt induction subject candidate aggressive induction regimen MDS refractory treatment HMA therapy recurrence progression MDS follow response HMA Has adequate organ function : AST ALT &lt; 3X ULN , serum bilirubin &lt; 2X ULN , serum creatinine &lt; 2 mg/dL , calculate creatinine clearance &gt; 50 mL/minute ECOG Performance Score 0 2 Recovered effect prior systemic therapy , radiotherapy surgery Willing use physician approve birth control method Current CNS Leukemia Acute promyelocytic leukemia AML ( 15 ; 17 ) ( q22 ; q12 ) cytogenetic abnormality Bcr/Abl positive leukemia &lt; 60 day ASCT ; chronic graftversus host disease ( GVHD ) require continued treatment systemic immunosuppressive agent Uncontrolled infection Known HIV , hepatitis B hepatitis C. Other active malignancy require therapy If female , lactate breast feeding Hypersensitivity PEG component AEB1102 ( CoArgIPEG )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
</DOC>